Renowned Microarray and Genomics Expert, Dr. Mansoor Mohammed, Joins CombiMatrix Molecular Diagnostics.NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ) announced today that renowned microarray and genomics expert Mansoor Mohammed, Ph.D. has joined CombiMatrix Molecular Diagnostics (CMDX) as its Chief Scientific Officer and a member of its Board of Directors. Dr. Mohammed has been at the forefront of research and development in the fields of Comparative Genomic Hybridization hybridization /hy·brid·iza·tion/ (hi?brid-i-za´shun) 1. crossbreeding; the act or process of producing hybrids. 2. molecular hybridization 3. (CGH CGH Comparative Genomic Hybridization CGH Changi General Hospital (Singapore) CGH Computer-Generated Hologram CGH Community General Hospital (Syracuse, NY) ) and microarray technologies for his entire professional career. Between 2001 and 2003 he produced the world's first commercially viable whole genome BAC BAC abbr. blood alcohol concentration array and co-authored one of its seminal clinical applications. A Bacterial Artificial Chromosome A bacterial artificial chromosome (BAC) is a DNA construct, based on a fertility plasmid (or F-plasmid), used for transforming and cloning in bacteria, usually E. coli. array is a highly efficient and accurate means of detecting genetic abnormalities responsible for a variety of human maladies, such as Down Syndrome, autism autism (ô`tĭzəm), developmental disability resulting from a neurological disorder that affects the normal functioning of the brain. It is characterized by the abnormal development of communication skills, social skills, and reasoning. , and cancer. Dr. Mohammed later directed the Advanced Technologies and Genomics program at Quest Diagnostics Incorporated, North America's largest commercial clinical laboratory. He is an internationally renowned scientist, speaker, and author and holds multiple patents in the fields of clinical genomics and microarray technology. "CGH is a powerful and transformative diagnostic tool that will complement CMDX's expertise in gene expression profiling," said Dr. Mohammed. "By bringing the two technologies together under one roof we will be able to provide our customers a truly comprehensive 'full spectrum genomic analysis.' I am very excited about joining CMDX and I look forward to helping the company develop and commercialize novel, high value gene-based diagnostic products and services that will assist physicians in making better treatment decisions for their patients." "I am delighted to have someone of Dr. Mohammed's caliber and profile within the clinical genomics community join the CMDX team," said Matt Watson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix Molecular Diagnostics. "As our Chief Scientific Officer he will play a critical role in helping CMDX become the country's premier center of excellence for molecular diagnostics." ABOUT DR. MOHAMMED Mansoor Mohammed, Ph.D. was trained as a molecular immunologist/geneticist at the University of Guelph The University of Guelph is a medium-sized university located in Guelph, Ontario, established in 1964. While the U of G offers degrees in many different disciplines, the university is best known for its focus on life sciences, based in part on a long-standing history of , Ontario, Canada (recently ranked Canada's top research university) where he earned a double major doctorate, with distinction. He received post-doctoral training in molecular immunology and clinical cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. at the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. (UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX ), where he trained and published with several world leading researchers including Drs. Charles Sawyers, M.D. and Eric Vilain, M.D., Ph.D. In 2001, Dr. Mohammed was recruited by Baylor College of Medicine Baylor College of Medicine is a private medical school located in Houston, Texas, USA on the grounds of the Texas Medical Center. It has been consistently rated the top medical school in Texas and among the best in the United States. to continue his clinical cytogenetics training, while directing the scientific research and development of a Baylor-sponsored start-up venture called Spectral Genomics, Inc. It was at Spectral that Dr. Mohammed produced the world's first commercially viable 1 Megabase human BAC array. Later, as Quest Diagnostics' Director of Advanced Technologies, he was honored with an Outstanding Performance Award (2003), the company-wide Medical Innovation Award (2004), and one of a select few Patent Innovation Awards (2005). Dr. Mohammed also serves as an ambassador of the sciences to the Toronto Genome Center of the renowned Toronto Hospital for Sick Kids. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group. The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 41 patent portfolios, which include over 150 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud Credit card fraud is a wide-ranging term for theft and fraud committed using a credit card or any similar payment mechanism as a fraudulent source of funds in a transaction. The purpose may be to obtain goods without paying, or to obtain unauthorized funds from an account. protection, database management, data encryption & product activation, digital media transmission (DMT See DSL. (R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS See eComStation. , image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software. Acacia Research-Acacia Technologies (NASDAQ:ACTG) and Acacia Research-CombiMatrix (NASDAQ:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com. Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion